Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost
about
HIV-Host Interactions: Implications for Vaccine DesignEpigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus VaccineHIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in MiceA Synthetic Porcine Reproductive and Respiratory Syndrome Virus Strain Confers Unprecedented Levels of Heterologous Protection.Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition.Natural infection as a blueprint for rational HIV vaccine design.A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.New approaches to HIV vaccine development.New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.Polyvalent vaccine approaches to combat HIV-1 diversityHIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-SpeciExpression, purification, and renaturation of a recombinant peptide-based HIV vaccine in Escherichia coli.HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells.Graph-based optimization of epitope coverage for vaccine antigen design.Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates.
P2860
Q26765966-26ACB70F-2010-4B08-86B8-94EF582D68F6Q28822525-C793095A-6C5A-418B-887C-AABD13EF3F96Q33869332-BD7226B1-1816-4F10-BFC2-272CC06D3D4DQ36079913-2061282E-C710-4CFD-8A30-54B14F865E90Q36281179-08DA0C8C-A312-4067-B318-1E403695D85DQ36756865-AF5339AE-6BC2-4BA0-9588-677343031577Q37619134-68098F1E-A728-448F-BC80-140C7D307DFBQ37656908-7BABE7FD-C001-4018-A094-18AFB28EBE0BQ38521826-CF362E1E-A2F3-490E-A9D0-37B2CA159DFDQ38748193-315F50DD-5102-4EF4-94F2-570FCE7276D6Q39108740-E6D75E42-1E5D-4D6B-A077-76588F35A445Q40339467-259807FC-66A4-4332-B0F7-922E19605CFEQ40344680-702E7675-DFC6-4D3D-BD9A-6C5101EFEC01Q40348395-846903BB-343C-4EA6-9CD2-74403FC86176Q40354550-268E39CE-B952-4CA5-926D-AC8FAD615C5DQ40579418-681D1970-7658-4E8A-9EF7-DE707098D247Q50043326-655CEAFA-7E23-4723-A95D-BADDD4CBEDCF
P2860
Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Comparison of Immunogenicity i ...... AC, and Envelope Protein Boost
@ast
Comparison of Immunogenicity i ...... AC, and Envelope Protein Boost
@en
type
label
Comparison of Immunogenicity i ...... AC, and Envelope Protein Boost
@ast
Comparison of Immunogenicity i ...... AC, and Envelope Protein Boost
@en
prefLabel
Comparison of Immunogenicity i ...... AC, and Envelope Protein Boost
@ast
Comparison of Immunogenicity i ...... AC, and Envelope Protein Boost
@en
P2093
P2860
P50
P356
P1433
P1476
Comparison of Immunogenicity i ...... AC, and Envelope Protein Boost
@en
P2093
Barbara K Felber
Beatriz Perdiguero
Bertram Jacobs
Elena E Giorgi
George N Pavlakis
Hua-Xin Liao
Jim Tartaglia
Karen Kibler
Kevin O Saunders
Krissey Lloyd
P2860
P304
P356
10.1128/JVI.00383-15
P407
P50
P577
2015-04-08T00:00:00Z